滤泡性淋巴瘤中期PET的预后作用:意大利淋巴瘤基金会FOLL12试验的事后研究
该事后研究分析了FOLL12随机试验中123例1-3a级滤泡性淋巴瘤患者,在免疫化疗第4至5周期之间行中期PET(iPET)并中心判读Deauville评分。iPET阴性者5年无进展生存率为70%,阳性者为34%;iPET阳性是多变量分析中无进展生存的独立预后因素。作者认为iPET是强预后因素,早期代谢反应评估可考虑用于设计早期反应适应型试验。
要点
- iPET阴性患者5年无进展生存率为70%,iPET阳性者为34%。
- iPET阳性是多变量分析中无进展生存的独立预后因素。
- iPET与诱导结束PET均阴性者3年无进展生存率为78%,进展风险低于双阳性者。
核心结论
- 结果证实,接受标准免疫化疗的滤泡性淋巴瘤患者中iPET是强预后因素。
- 作者认为滤泡性淋巴瘤的早期代谢反应评估可考虑用于定义新一代早期反应适应型试验。
研究设计与样本
- FOLL12随机试验的事后研究,纳入211例有iPET患者中的123例进行中心判读。
- 纳入1-3a级滤泡性淋巴瘤患者,iPET于一线免疫化疗第4至5周期之间进行。
- PET由中心判读确定Deauville评分(DS),DS 4-5定义为阳性。
- 患者中43%年龄大于60岁,33%为高危FLIPI2,47%接受利妥昔单抗-苯达莫司汀诱导。
- 试验注册号为NCT02063685。
主要发现
- iPET显示完全代谢缓解(CMR)者占83%。
- iPET阴性患者中91%在诱导结束PET(eoiPET)确认CMR。
- 5年无进展生存率:iPET阴性者70%,iPET阳性者34%。
- iPET与eoiPET均阴性者3年无进展生存率为78%,较iPET/eoiPET双阳性者进展风险降低。
- 5年总生存率:iPET阴性者96%,DS 4-5者85%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We analyzed metabolic response using interim positron emission tomography scan (iPET) in a subset of patients with follicular lymphoma (FL) enrolled in the randomized FOLL12 trial. Patients with grade 1-3a FL with an iPET performed between cycles 4 and 5 of first-line immunochemotherapy (ICT) were included; PET scan had to be centrally reviewed for the definition of Deauville score (DS) and were considered positive for DS 4-5. Overall 123 patients out of 211 with iPET were available for central review. Of these, 43% were older than 60, 33% had high-risk FLIPI2, and 47% received rituximab-bendamustine as the induction regimen. iPET showed a complete metabolic response (CMR) in 83% of cases. CMR at the end-of-induction therapy PET scan (eoiPET) was confirmed in 91% of iPET-negative patients. The 5-year progression-free survival (PFS) was 70% for iPET-negative and 34% for iPET-positive cases. In multivariate analysis, positive iPET was an independent prognostic factor for PFS. Combining iPET and eoiPET, the 3-year PFS was 78% for both negative iPET and eoiPET, with a reduced risk of progression compared to double-positive iPET/eoiPET cases. The 5-year overall survival rate was 96% for iPET-negative and 85% for DS 4-5. Our results confirm that iPET in patients with FL treated with standard ICT is a strong prognostic factor. Assessment of early metabolic response in FL may be considered for defining a novel generation of early response-adapted trials in FL. This trial was registered at www.ClinicalTrials.gov as #NCT02063685.
引用
- Durmo R, Chauvie S, Fallanca F, et al. Prognostic role of interim PET in follicular lymphoma: a post hoc study of FOLL12 trial by Fondazione Italiana Linfomi. Blood Adv. 2025. PMID: 40106688. doi:10.1182/bloodadvances.2024014790
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。